Gerber-FTC Settlement Stipulates Clinical Trials For Infant Formula Claims
Executive Summary
FTC filed its complaint in 2014 alleging Gerber, part of Nestlé Nutrition North America, deceptively advertised that feeding Good Start Gentle formula to infants with a family history of allergies prevents or reduces the risk that the infants will develop allergies.
You may also be interested in...
US Wellness Market In 2019: Amarin Wins, Loses On Supplements; Gottlieb Leaves With Consumer Health Flourish
Looking look back on US wellness market developments and events in 2019, HBW Insight finds a firm that doesn’t compete in the dietary supplement sector, Amarin, made a good bit of news that affected the industry during the year. We track news across the wellness space from the past year.
Clinical Trials For Supplement Claims Not An FTC Rule, But A Standard
FTC Bureau of Consumer Protection official Richard Cleland takes on the hot-button issue by explaining that a supplement health or structure/function claim doesn't need support from research with the size and scope of studies looking at the safety and efficacy of a drug ingredient proposed for a certain indication. Supplement ad claims, though, still need competent and reliable scientific evidence as support.
FDA Warning On Gerber Formula Claims Strikes Familiar Chord With FTC Complaint
An FDA warning letter to Nestle Infant Nutrition says Gerber Good Start Gentle’s labeling and the product’s website omit or obscure required disclaimers, rendering qualified health claims as unauthorized, and mischaracterize the product’s formulation.